Cure - Pharmaceutical
Pharmaceutical
About Us
Contact
Toggle menu
Investors
Cure
>
Investors
PROPRIETARY BENEFITS
De-risked due to approved API and proven delivery system
Patent reinforcing to further
protect technology
Additional significant revenue from
exclusive manufacturing contracts
Interested parties may contact:
Mark Udell, Chief Financial Officer at
Mudell@curepharma.com